Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I would have to agree with you there. 2017 has proven to be an extremely uneventful year for Anavex so far...really hoping the tune changes in the coming weeks.
Ah yes, the ol' "waiting for PK data" story. I've been long since February 2015 but this whole PK data thing is starting to get a little ridiculous...
Man I understand there's a bunch of manipulation going on here but this past month has been down right depressing for OBMP investors. Hoping Dr. Head can provide the market with some reassurance that everything's still on track. I'm currently down about 90% from my average position...
If this is for 2-73 PLUS, I wonder what % of the compound needs to be donepezil to qualify. It appears monotherapy has been performing significantly better than 2-73 PLUS, but could we get around this by only adding a miniscule amount of donepezil?
Yep, I've been long for the past year or so. Lots of exciting catalysts coming down the pipe!
Very interesting - thanks for sharing! It's mind boggling how few people are aware of this stock...
If they're designing the upcoming trial to target strong responder qualities known from 2a, we could see that percentage increase substantially in Phase 2/3. Really looking forward to the PkPd/Ariana analysis to provide us with key insights that optimize our chance of succeeding.
Very interesting... thank you for the share!!
Thanks for sharing, Dan!
OncBioMune Announces Term Sheet to Acquire Norepinefrine from Teva Pharmaceuticals in Mexico
BATON ROUGE, LA--(March 20, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce the signing of a non-binding term sheet ("Term Sheet") with NYSE-listed Teva Pharmaceuticals Industries Ltd. ("Teva"), the world's largest generic medicines producer, with regards to Norepinefrine for the Mexican market. This registration can as well be used in other Central and Latin American countries and will be selected by own discretion.
The term sheet confirms mutual interest and sets forth guidelines for OncBioMune to acquire the sanitary registration and intellectual property rights of Norepinefrine currently owned by Teva. Norepinefrine is approved in Mexico as indicated for the treatment of low blood pressure and heart failure.
Similar to the agreement announced last week involving OncBioMune's negotiations with Eddingpharm (Taizhou) Co., Ltd.'s U.S. subsidiary EOC Pharma Ltd., the Term Sheet originated through discussions between Vitel Laboratorios S.A. de C.V. ("Vitel") and Teva during the process of OncBioMune acquiring Vitel. On March 10, 2017, OncBioMune completed the acquisition of Vitel. Teva has since informed OncBioMune of its interest in moving forward towards a definitive agreement detailing the acquisition of Norepinefrine by OncBioMune.
"Mexico is one of the top five emerging markets globally, principally with generics. Teva has a broad portfolio of generics that are overlapping in some strategic markets, which presented an opportunity for us to acquire another revenue-generating drug," commented Jonathan Head, Ph. D., Chief Executive Officer at OncBioMune. "We intend to remain aggressive in our acquisition strategy to grow our high specialty footprint in Mexico and across all of Central and South America to capitalize on the burgeoning markets. Pending the unexpected, I anticipate a definitive agreement and our acquisition of Norepinefrine during the second quarter of 2017, with commercialization efforts to commence shortly thereafter."
Glad to hear. Do you mind sharing what you read that calmed your doubts?
I appreciate the honest, well thought out post, Whiskey/Sausage! Thanks for trying to stay realistic in the midst of all these unknowns.
OncBioMune Acquires Vitel Laboratorios, Gains Two Revenue Generating Drugs, Robust Pipeline and Extensive Distribution Network
BATON ROUGE, LA--(March 13, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce the completion of its previously announced plans to acquire Vitel Laboratorios, S.A. de C.V. ("Vitel") on March 10, 2017.
The acquisition of Vitel is expected to transform OncBioMune into a revenue-generating international pharmaceutical company with a more diverse product line with a particularly deep reach throughout Mexico, Central and Latin America, and relationships across Europe and Asia. The acquisition of Vitel includes two drugs it licenses and sells in Mexico, Bekunis® for constipation and Cirkused® for stress. Approved for sale in the fourth quarter of 2016, the two over-the-counter products have generate significant sales that have exceeded Vitel's early projections. Vitel has a total of seven other products that are either already in the registration stage or planned for launch later in 2017.
The acquisition of Vitel includes its 50% ownership interest in Oncbiomune México, S.A. De C.V., a Mexican company ("Oncbiomune Mexico"), an entity we jointly launched with Vitel in August 2016. Oncbiomune Mexico was launched for the purposes of developing and commercializing our PROSCAVAX vaccine technology and cancer technologies in México, Central and Latin America ("MALA") for the treatment of prostate, ovarian and various other types of cancer and includes a portfolio of owned products and licenses with OncBioMune.
Vitel founder Manuel Cosme Odabachian, an expert in drug licensing, development and marketing, will join OncBioMune as General Manager of Global Operations and take over Mr. Kucharchuk' s role as a member of our Board of Directors. In addition to overseeing Vitel's Mexican operations, including the upcoming Phase 2/3 trial of ProscaVax for prostate cancer already in motion through our Oncbiomune Mexico joint venture with Vitel, Mr. Odabachian will spearhead ongoing and future international negotiations to further broaden our expanding portfolio, with a focus on drugs in advanced stages of development or already on the market.
"The acquisition of Vitel is expected to add a great deal of value to OncBioMune and represents a major milestone that immediately leapfrogs us years ahead in development, while providing cash flow to help fund development of our pipeline and commercialization of even more products," said Jonathan Head, Ph. D., Chief Executive Officer at OncBioMune. "Bringing Vitel under our umbrella gives us a formidable network and international presence that opens the door to a litany of possibilities towards meeting our goals. Our mid-term plan is continuing to build shareholder value through the clinical development of ProscaVax in the U.S. and Mexico, maintaining an aggressive position on growing our revenue streams through licensing/acquisition of additional drugs for the international markets and positioning us to seek qualification for an listing on a national stock exchange."
"Additionally, I am excited to work with Manuel as a new member of our leadership team," added Dr. Head. "His years of experience, industry connections and history of tremendous successes will be invaluable in our efforts to regularly attain new milestones."
Vitel has license agreements covering the Mexican market with Roha Arnzemittel, GmbH ("Roha") for Bekunis® (for constipation) and Cirkused® (for stress), as well as licensing rights to the remainder of Roha's pipeline at Vitel's discretion.
Vitel also has Mexican territorial rights through licensing agreements with; Kamada for KamRab® (for rabies), KamRho® (an Rh immunization) and Glassia® (for Anti-D deficiency); Aqvida for Imatinib (for cancer), and other oncology products; QPharma for Androferti (a male fertility drug) and is currently developing two innovative orphan drugs through their own research and development.
For Mexico, Central and Latin America, Vitel has relationships that are expected to forge development and commercialization of several products, including, Gem Pharmaceuticals for GPX-150 (for sarcoma); EOC Pharma for Telatinib (for first line oral gastric cancer treatment); and Rational Vaccines for the first and only herpes Vaccine technology for the treatment of HSV-2 and HSV-1.
In addition to its product pipeline and relationships, Vitel's network channel partners cover a wide range of drug development and marketing. A sampling of relationships includes, CID Information Systems (marketing intelligence), Grupo Nichos (pharmaceutical salesforce, demand generation), CeroGrados (pharmaceutical warehousing, and old chain), CRO's authorized by the COFEPRIS and Regulatory Affairs parties that are authorized by the COFEPRIS for dossier build up and pre-inspection.
The acquisition of Vitel is structured as an all-stock transaction. The current shareholders in Vitel will exchange their shares for our newly-issued restricted common stock and voting preferred stock. Additional details of the acquisition can be found in the Company's Form 8-K filed with the Securities and Exchange Commission and on the OncBioMune website.
Been loving this support lately. Still relatively unknown in the market...I think the April presentation will really help spread the word. I hope there's a live stream available!
...who also happen to be presenting right before Missling on March 30th on the topic, "Combination therapy era will emerge for Alzheimer's disease modification in the near future"...
Damn, gaining some traction here. You're right...the merger should be about finalized by now. Looking forward to the April poster presentation! We may continue to see momentum leading up to it in anticipation of positive data...
Lol under $3! Willing to bet on that?
Lol I guess that would explain his mane!
Great summary, thanks Franz! I also watched and agree with your perspective. Missling did a great job...I was impressed!
Lol yep this is a weekly occurrence for them...like the article published less than a week ago titled, "Forget Anavex Life Sciences Corp.: These 2 Biotech Stocks Are Better Buys". They aren't fooling anyone but themselves...
Likewise! Seems like we're slowly starting to get the word out there...this could be a very interesting next couple of months for OBMP.
Strong open this morning!
Apparently George Perry, PhD, is incapable of doing a simple Google search since he said he's never seen results like this before. I guess you think the guy must be a fraud or something, right?
While I don't want to dwell on the patent concerns, I found it interesting that donepezil was mentioned twice in the investor presentation posted today:
- "Similar positive MMSE score effect and no notable difference between ANAVEX 2-73 alone and ANAVEX 2-73 with donepezil observed"
- "Temporary improvement in P300 amplitude seen with donepezil therapy persists with ANAVEX 2-73"
Doesn't come across as very synergistic to me...
Awesome, definitely seems like a change of momentum with new money coming in. Hopefully this trend is just the beginning...
Picking up steam here! Have you broken even yet? Word's slowly starting to spread...
Decent news announced today:
Departments of Urology and Oncology Approve Protocol for OncBioMune's Phase 2/3 Trial of ProscaVax for Prostate Cancer in Mexico
OncBioMune Pharmaceuticals, Inc. (OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce the receipt of acknowledgement and authorization to perform the protocol proposed for the Phase 2/3 clinical trial of ProscaVax from the Department of Urology of the High Specialty Hospital IMSS Siglo XXI ("HSH IMSS") in Mexico. The clinical study is being sponsored by OncBioMune Mexico S.A. de C.V., a joint venture between the Company and its planned acquisition target, Vitel Laboratorios S.A. de C.V., and being conducted at HSH IMSS, which is considered the foremost government hospital in Mexico.
In the study, ProscaVax, OncBioMune's lead experimental therapeutic cancer vaccine, will be evaluated for safety and efficacy in prostate specific antigen (PSA) recurrent prostate cancer in hormone-naïve and hormone-independent patients.
The authorization from the Department of Urology follows a recently received authorization to perform the protocol from the Department of Oncology at HSH IMSS.
"Receiving authorization from both departments was not necessary and is a tremendous vote of confidence that directors of each unit are interested in participating in the clinical trial," commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. "We now have the full weight and expertise of each department to oversee the study, support gathering patients for enrollment and all the equipment required to complete the protocol in hand. This is an incredible asset for us and should help ensure an efficiently run trial."
Thanks BooDog! Am liking the increase in volume today. Will keep the news alerts set...our day will come!! I appreciate the posts!
Thanks for keeping us grounded scottsmith. The press will jump all over this when we announce partnership and/or phase II/III data. I don't see substantial momentum until then...I've been accumulating in the meantime.
How much lower do you see this going, BooDog? I've been trying to average down but every time it just goes lower. We're due for a nice climb this quarter!
Interesting theory, thank you!
My only hesitation about monotherapy steps from our July 2016 AAIC poster:
"Positive MMSR score effect with ANAVEX 2-73 alone and no notable difference observed on MMSE score between ANAVEX 2-73 alone and ANAVEX 2-73 with donepezil."
Perhaps we'll see improvements in other areas (besides MMSE) if all trial participants did in fact switch to monotherapy?
Phenomenal post - very much appreciated!!
Do you have a source for the 6-12 month quote? Still optimistic for financing news before year end...
I'd argue there are indeed concerns with every new indication announced: funding and focus. It's great to have a broad drug portfolio, but I'm also well aware we have limited cash resources at the present time. It's a delicate balance - I'm glad AVXL isn't trying to be a one-trick pony, however the financing of all these indications does not come cheap. It is perfectly reasonable for "true longs" like myself to have financing concerns.
Lol was that sarcasm? The news many of us await hopefully contains the words "Phase 3" and "partnership". Another model data PR just makes us more vulnerable to a short attack from the usual culprits...
The market is going INSANE over this news...check out that volume spike! (Lol). Lots of patience needed here...
OncBioMune Broadens Portfolio, Partners and Product with Vitel Acquisition
OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to provide shareholders additional insight as to the Company's ongoing initiative to acquire Mexican Joint Venture partner Vitel Laboratorios, S.A. de C.V. ("Vitel"). In September, OncBioMune disclosed negotiating a potential merger, which resulted in the signing of a non-binding term sheet, as disclosed on November 3, 2016. The legal teams for each company are actively working on definitive agreement documents to create a binding arrangement, which would entail Vitel becoming a wholly owned subsidiary of OncBioMune.
Currently, OncBioMune and Vitel have agreed in principle that the acquisition will transfer rights to Vitel's portfolio of products to OncBioMune, as well as establish new relationship between OncBioMune and Vitel's current network of distribution, proprietary rights, Joint Venture and licensing partners.
Vitel presently has Mexican territorial rights through licensing agreements with Roha Arnzemittel, GmbH ("Roha") for Bekunis® (for constipation) and Cirkused® (for stress), as well as licensing rights to the remainder of Roha's pipeline at Vitel's discretion. These products were commercialized in September by Vitel and have generated approximately $100,000USD in revenue in approximately six weeks of an initial re-launch to the Mexican markets.
Vitel also has Mexican territorial rights through licensing agreements with Cheplapharm Arzneimittel GmbH for Vesanoid® (for cancer); Kamada for KamRab® (for rabies), KamRho® (an Rh immunization) and Glassia® (for Anti-D deficiency); Aqvida for Imatinib (for cancer), Docetaxel (for cancer), Azathriopine (an immunosuppressive drug); and QPharma for Androferti (a male fertility drug).
For Mexico, Central and Latin America, Vitel has Joint Venture partnerships forged for development and commercialization of several products, including, Gem Pharmaceuticals for GPX-150 (for sarcoma); EOC Pharma for Telatinib (for first line gastric cancer treatment); and Rational Vaccines for the first and only herpes Vaccine technology for the treatment of HSV-2 and HSV-1.
Further, Vitel is under development of world right agreements with confidential partners for the moment, where R&D and unique innovation is involved.
In addition to the product pipeline and partners, Vitel's network channel partners cover the gamut of drug development and marketing. A sampling of relationships includes, CID Information Systems (marketing intelligence), Grupo Nichos (pharmaceutical salesforce, demand generation), CeroGrados (pharmaceutical warehousing, and old chain), CRO's authorized by the COFEPRIS and Regulatory Affairs parties that are authorized by the COFEPRIS for dossier build up and pre-inspection.
"I think it is pretty clear why we are excited to be working with Vitel on ProscaVax for development south of the U.S. border and why the acquisition of Vitel brings tremendous value to OncBioMune from the outset," commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. "The long standing relationships they have with some of the venerable companies in the pharmaceutical space in Mexico and throughout Latin America is something that takes years to develop. Upon completing the acquisition we immediately become a respected player in the space, which will be invaluable with moving forward with our aggressive growth plans."
While the acquisition is moving forward in good faith, interested parties are advised that the acquisition of Vitel by OncBioMune remains subject to the execution of a definitive agreement containing customary representations, warranties, and closing conditions, completion of due diligence and approval by the respective boards of directors of OncBioMune and Vitel.
I'm thinking we'll continue to hover
around the .10-.18 zone until significant news hits. While I understand this stock is relatively unknown to the majority of investors, the market has made it pretty clear that we absolutely need better financing if we want to move forward with our plan. Hopefully the Vitel acquisition details benefit us in that respect. The latest PR update states a US Phase 2 in "early 2017", which is about a year later than originally anticipated when the company went public. Dr Head will need to prove to investors that he's serious about the direction of OMBP if we want big pharma to take us seriously.
I appreciate the thorough response...thank you! Looking forward to watching this deal develop in the coming weeks!